Search
Albutrepenonacog alfa
go.drugbank.com/drugs/DB13884ApprovedIt is currently marketed in the forms of 250, 500, 1000 and 2000 IU/vial.[L2305] … Albutrepenonacog alfa (rIX-RFP) is a recombinant fusion protein that links a recombinant coagulation factor IX (rFIX) with a recombinant human albumin (rAlbumin).
Products: ไอเดลวิออน 500, IDELVION 1000 IU powder and solvent for solution for injectionIfosfamide
go.drugbank.com/drugs/DB01181ApprovedInvestigationalIfosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
Categories: Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexSynonyms: 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxideDoxapram
go.drugbank.com/drugs/DB00561ApprovedInvestigationalVet approvedA central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
Categories: Heterocyclic Compounds, 1-RingSynonyms: 1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinonePrednisolone phosphate
go.drugbank.com/drugs/DB14631ApprovedInvestigationalVet approvedPrednisolone phosphate is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.
Mixtures: OFTALETYC® NFCategories: P-glycoprotein inducers, Cytochrome P-450 CYP2A6 InducersAbciximab
go.drugbank.com/drugs/DB00054ApprovedWithdrawnAbciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. … Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules
Products: CLOTİNAB 10 MG/5 ML IV ENJEKSİYON İÇİN ÇÖZELTİ İÇEREN FLAKON, 1 ADET, ReoPro 2 mg/ml Injektionslösung oder InfusionslösungY+L amino acid transporter 2
go.drugbank.com/bio_entities/BE0009872TransporterHumansAlso exchanges L-arginine with L-lysine in a sodium-independent manner (PubMed:10903140). The transport mechanism is electroneutral and operates with a stoichiometry of 1:1 (PubMed:10903140). … May also transport glycine betaine in a sodium dependent manner from the cumulus granulosa into the enclosed oocyte (By similarity)
Polypeptides: Y+L amino acid transporter 2Synonyms: Y+LAT2, y+LAT-2Neuropeptide Y receptor type 4-2
go.drugbank.com/bio_entities/BE0024014TargetHumansG protein-coupled receptor for PPY/pancreatic polypeptide/PP, NPY/neuropeptide Y and PYY/peptide YY that is negatively coupled to cAMP. … The rank order of affinity for these polypeptides and their derivatives is PP, PP (2-36) and [Ile-31, Gln-34] PP > [Pro-34] PYY > PYY and [Leu-31, Pro-34] NPY > NPY > PYY (3-36) and NPY (2-36) > PP (13
Polypeptides: Neuropeptide Y receptor type 4-2Brigatinib
go.drugbank.com/drugs/DB12267ApprovedInvestigational[A31311] It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. … [A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026]
Mixtures: ALUNBRİG 90 MG VE 180 MG FİLM KAPLI TABLET TEDAVİYE BAŞLANGIÇ PAKETİ, 7 ADET 90 MG VE 21 ADET 180 MG, ALUNBRİG 90 MG VE 180 MG FİLM KAPLI TABLET TEDAVİYE BAŞLANGIÇ PAKETİ, 7 ADET 90 MG VE 21 ADET 180 MGCategories: Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexDonepezil
go.drugbank.com/drugs/DB00843ApprovedInvestigationalIn 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. … [L7916,L7937] A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia.
Mixtures: EBICOMB 5 MG/20 MG EFERVESAN TABLET, 100 ADET, EBICOMB 5 MG/10 MG EFERVESAN TABLET, 100 ADETCategories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingLapatinib
go.drugbank.com/drugs/DB01259ApprovedInvestigationalLapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. … Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine